Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cell (900th Hospital of Joint Logistics Support Force of PLA)
- Development stage
- Unknown
- Lead developer
- 900th Hospital of Joint Logistics Support Force of PLA
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Mesenchymal stem cells (MSCs) are multipotent stromal cells being investigated by Fuzhou General Hospital for the treatment of chronic allograft nephropathy (CAN) in kidney transplant recipients. MSCs possess unique immunomodulatory and regenerative properties, which are leveraged to prevent organ rejection and maintain long-term kidney function. By secreting various cytokines and growth factors, MSCs can suppress the activation of T-cells and other immune cells involved in graft rejection while promoting the repair of damaged renal tissues. This cell-based therapy aims to reduce the reliance on traditional immunosuppressive drugs and improve the longevity of the transplanted organ. In the specific context of Fuzhou General Hospital's research, these cells are typically expanded ex vivo before being infused into patients who have developed signs of chronic graft failure.
- Other names
- MSCmesenchymal stromal cellsbone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on mesenchymal stem cell (900th Hospital of Joint Logistics Support Force of PLA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cell (900th Hospital of Joint Logistics Support Force of PLA).